UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 48

Sortiert nach

The Poly(ADP-ribose) Polymerase PARP-1 Is Required for Oxidative Stress-induced TRPM2 Activation in Lymphocytes

The Journal of biological chemistry, 2008-09, Vol.283 (36), p.24571-24583

2008

Volltextzugriff (PDF)

Correction: The BRCT Domain of PARP-1 Is Required for Immunoglobulin Gene Conversion

PLoS biology, 2018-03, Vol.16 (3), p.e1002621-e1002621

2018

Volltextzugriff (PDF)

The BRCT domain of PARP-1 is required for immunoglobulin gene conversion

PLoS biology, 2010-07, Vol.8 (7), p.e1000428

2010

Volltextzugriff (PDF)

Attenuating CD3 affinity in a PSMAxCD3 bispecific antibody enables killing of prostate tumor cells with reduced cytokine release

Journal for immunotherapy of cancer, 2021-06, Vol.9 (6), p.e002488

2021

Volltextzugriff (PDF)

S224: HIGH COMPLETE RESPONSE RATE WITH TNB‐486, A NOVEL CD19XCD3 T‐CELL ENGAGER, IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA: INTERIM RESULTS FROM AN ONGOING PHASE 1 STUDY

HemaSphere, 2023-08, Vol.7 (S3), p.e60614fc-n/a

2023

Volltextzugriff (PDF)

Ex vivo efficacy of BCMA‐bispecific antibody TNB‐383B in relapsed/refractory multiple myeloma

EJHaem, 2020-07, Vol.1 (1), p.113-121

2020

Volltextzugriff (PDF)

Characterization of parameters required for effective use of tamoxifen-regulated recombination

PloS one, 2008-09, Vol.3 (9), p.e3264-e3264

2008

Volltextzugriff (PDF)

Fusobacterium Liver Abscess

Case reports in gastroenterology, 2013-11, Vol.7 (3), p.482-486

2013

Volltextzugriff (PDF)

Structure/function analysis of PARP-1 in oxidative and nitrosative stress-induced monomeric ADPR formation

PloS one, 2009-07, Vol.4 (7), p.e6339-e6339

2009

Volltextzugriff (PDF)

A Phase I First-in-Human Study of ABBV-383, a B-Cell Maturation Antigen × CD3 Bispecific T-Cell Redirecting Antibody, in Patients With Relapsed/Refractory Multiple Myeloma

Journal of clinical oncology, 2022-11, Vol.40 (31), p.3576-3586

2022

Volltextzugriff (PDF)

Initial Results of a Phase I Study of TNB-383B, a BCMA x CD3 Bispecific T-Cell Redirecting Antibody, in Relapsed/Refractory Multiple Myeloma

Blood, 2020-11, Vol.136 (Supplement 1), p.43-44

2020

Volltextzugriff (PDF)

Efficient tumor killing and minimal cytokine release with novel T-cell agonist bispecific antibodies

mAbs, 2019-05, Vol.11 (4), p.639-652

2019

Volltextzugriff (PDF)

Interim Results of the Phase 1 Study of Tnb-486, a Novel CD19xCD3 T-Cell Engager, in Patients with Relapsed/Refractory (R/R) B-NHL

Blood, 2022-11, Vol.140 (Supplement 1), p.1474-1475

2022

Volltextzugriff (PDF)

High complete response rate with TNB-486 in relapsed/refractory follicular lymphoma: Interim results from an ongoing phase 1 study

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.7524-7524

2023

Volltextzugriff (PDF)

TNB585.001: A multicenter, phase 1, open-label, dose-escalation and expansion study of tnb-585, a bispecific T-cell engager targeting PSMA in subjects with metastatic castrate resistant prostate cancer

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.TPS5092-TPS5092

2021

Volltextzugriff (PDF)

Requirements for DNA Unpairing during Displacement Synthesis by HIV-1 Reverse Transcriptase

The Journal of biological chemistry, 2004-12, Vol.279 (51), p.52924-52933

2004

Volltextzugriff (PDF)

TNB383B.0001: A Multicenter, Phase 1, Open-Label, Dose-Escalation Andexpansion Study of TNB-383B, a Bispecific Antibodytargeting BCMA in Subjects with Relapsed or Refractorymultiple Myeloma

Blood, 2019-11, Vol.134 (Supplement_1), p.1874-1874

2019

Volltextzugriff (PDF)

A Phase 1 First-in-Human Study of Tnb-383B, a BCMA x CD3 Bispecific T-Cell Redirecting Antibody, in Patients with Relapsed/Refractory Multiple Myeloma

Blood, 2021-11, Vol.138 (Supplement 1), p.900-900

2021

Volltextzugriff (PDF)

T Cells Expressing Anti-B-Cell Maturation Antigen (BCMA) Chimeric Antigen Receptors with Antigen Recognition Domains Made up of Only Single Human Heavy Chain Variable Domains Specifically Recognize Bcma and Eradicate Tumors in Mice

Blood, 2017-12, Vol.130, p.504-504

2017

Volltextzugriff (PDF)

A novel CD3xPSMA bispecific antibody for efficient T cell mediated killing of prostate tumor cells with minimal cytokine release

Journal of clinical oncology, 2019-03, Vol.37 (7_suppl), p.324-324

2019

Volltextzugriff (PDF)

Effect of modulation of CD3 binding in a PSMAxCD3 T-cell engaging bispecific antibody on maintenance of efficient tumor cell kill and cytokine release

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.e17583-e17583

2020

Volltextzugriff (PDF)

A CD3 x FRα T-cell engaging bispecific antibody for efficient killing of ovarian cancer cells with minimal cytokine release

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.e18050-e18050

2020

Volltextzugriff (PDF)

Abstract 1554: Uncoupling tumor-cell cytotoxicity from cytokine release with novel T-cell engaging bispecific antibodies

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.1554-1554

2019

Volltextzugriff (PDF)

TNB-486, a Novel Fully Human Bispecific CD19 x CD3 Antibody That Kills CD19-Positive Tumor Cells with Minimal Cytokine Secretion

Blood, 2019-11, Vol.134 (Supplement_1), p.4070-4070

2019

Volltextzugriff (PDF)

1 – 25 von 48

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(45)
Mit Volltextzugriff
(46)

Publikationsform

Sprache

Englisch
(48)
Japanisch
(3)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

The Poly(ADP-ribose) Polymerase PARP-1 Is Required for Oxidative Stress-induced TRPM2 Activation in Lymphocytes

Correction: The BRCT Domain of PARP-1 Is Required for Immunoglobulin Gene Conversion

The BRCT domain of PARP-1 is required for immunoglobulin gene conversion

Attenuating CD3 affinity in a PSMAxCD3 bispecific antibody enables killing of prostate tumor cells with reduced cytokine release

A T-cell engaging bispecific antibody with a tumor-selective bivalent folate receptor alpha binding arm for the treatment of ovarian cancer

S224: HIGH COMPLETE RESPONSE RATE WITH TNB‐486, A NOVEL CD19XCD3 T‐CELL ENGAGER, IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA: INTERIM RESULTS FROM AN ONGOING PHASE 1 STUDY

Ex vivo efficacy of BCMA‐bispecific antibody TNB‐383B in relapsed/refractory multiple myeloma

Characterization of parameters required for effective use of tamoxifen-regulated recombination

Fusobacterium Liver Abscess

Structure/function analysis of PARP-1 in oxidative and nitrosative stress-induced monomeric ADPR formation

A Phase I First-in-Human Study of ABBV-383, a B-Cell Maturation Antigen × CD3 Bispecific T-Cell Redirecting Antibody, in Patients With Relapsed/Refractory Multiple Myeloma

Initial Results of a Phase I Study of TNB-383B, a BCMA x CD3 Bispecific T-Cell Redirecting Antibody, in Relapsed/Refractory Multiple Myeloma

Efficient tumor killing and minimal cytokine release with novel T-cell agonist bispecific antibodies

Interim Results of the Phase 1 Study of Tnb-486, a Novel CD19xCD3 T-Cell Engager, in Patients with Relapsed/Refractory (R/R) B-NHL

High complete response rate with TNB-486 in relapsed/refractory follicular lymphoma: Interim results from an ongoing phase 1 study

TNB585.001: A multicenter, phase 1, open-label, dose-escalation and expansion study of tnb-585, a bispecific T-cell engager targeting PSMA in subjects with metastatic castrate resistant prostate cancer

Requirements for DNA Unpairing during Displacement Synthesis by HIV-1 Reverse Transcriptase

TNB383B.0001: A Multicenter, Phase 1, Open-Label, Dose-Escalation Andexpansion Study of TNB-383B, a Bispecific Antibodytargeting BCMA in Subjects with Relapsed or Refractorymultiple Myeloma

A Phase 1 First-in-Human Study of Tnb-383B, a BCMA x CD3 Bispecific T-Cell Redirecting Antibody, in Patients with Relapsed/Refractory Multiple Myeloma

T Cells Expressing Anti-B-Cell Maturation Antigen (BCMA) Chimeric Antigen Receptors with Antigen Recognition Domains Made up of Only Single Human Heavy Chain Variable Domains Specifically Recognize Bcma and Eradicate Tumors in Mice

A novel CD3xPSMA bispecific antibody for efficient T cell mediated killing of prostate tumor cells with minimal cytokine release

Effect of modulation of CD3 binding in a PSMAxCD3 T-cell engaging bispecific antibody on maintenance of efficient tumor cell kill and cytokine release

A CD3 x FRα T-cell engaging bispecific antibody for efficient killing of ovarian cancer cells with minimal cytokine release

Abstract 1554: Uncoupling tumor-cell cytotoxicity from cytokine release with novel T-cell engaging bispecific antibodies

TNB-486, a Novel Fully Human Bispecific CD19 x CD3 Antibody That Kills CD19-Positive Tumor Cells with Minimal Cytokine Secretion

Suchergebnisse filtern